Table of Content

1 Market Definition
1.1 Inclusion and Exclusion Criteria

2 Research Scope
2.1 Target Audience
2.2 Key Questions Answered in the Report

3 Research Methodology
3.1 Global Extensive Stage Small Cell Lung Cancer Market: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Target Patient Pool Estimation Model
3.5 Criteria for Company Profiling

4 Markets
4.1 Market Overview
4.1.1 Market Landscape
4.1.1.1 Strategic Activities
4.1.1.2 Regional Distribution of Companies
4.1.2 Market Dynamics
4.1.2.1 Market Drivers
4.1.2.1.1 Introduction of Immune Checkpoint Inhibitors in Combination with Platinum-Based Chemotherapy as Mainstay Treatment
4.1.2.1.2 Next-Generation Sequencing is Helping in Identifying New Molecular Targets
4.1.2.1.3 Need of Potential Treatments to Improve Quality of Life of Extensive Stage Small Cell Lung Cancer Patients
4.1.2.2 Market Restraints
4.1.2.2.1 Lack of Early Detection Methods for Extensive Stage Small Cell Lung Cancer
4.1.2.2.2 Poor Disease Prognosis of Extensive Stage Small Cell Lung Cancer
4.1.2.3 Opportunities
4.1.2.3.1 Approval of Immune Checkpoint Inhbitors as Combination Therapy Broadens the Horizon
4.1.2.3.2 Lack of Approved Treatments for Extensive Stage Small Cell Lung Cancer Relapsed Patients

5 Indication
5.1 Extensive Stage Small Cell Lung Cancer (ES-SCLC)
5.1.1 Disease Overview
5.1.2 Causes and Risk Factors
5.1.3 Disease Pathophysiology
5.1.3.1 Disease Staging
5.1.4 Symptoms
5.1.5 Treatment Landscape
5.1.5.1 Treatment Overview
5.1.5.2 Treatment Types
5.1.5.3 Treatment Guidelines for Extensive Stage Small Cell Lung Cancer Patients
5.1.5.4 Treatment Algorithm
5.1.6 Unmet Needs
5.1.6.1 Lack of Therapeutic Efficacy of the Existing Treatments
5.1.6.2 Treatment-Related Side Effects Impacting Overall Quality of Life
5.1.7 Patient Journey

6 Region
6.1 U.S.
6.2 U.K.
6.3 Germany
6.4 France
6.5 Italy
6.6 Spain
6.7 Japan

7 Products
7.1 Global Extensive Stage Small Cell Lung Cancer Market Pipeline Analysis (by Phase)
7.1.1 Development Phase
7.1.2 Drug Class
7.1.3 Route of Administration (RoA)
7.1.4 Monotherapy/Combination Therapy Type
7.2 Marketed Products
7.2.1 Zepzelca (Lurbinectedine)
7.2.1.1 Overview
7.2.1.2 Commercial Overview
7.2.1.2.1 Strategic Activities
7.2.1.2.2 Regulatory Overview
7.2.1.3 Clinical Overview
7.2.2 Cosela (Trilaciclib)
7.2.2.1 Overview
7.2.2.2 Commercial Overview
7.2.2.2.1 Strategic Activities
7.2.2.2.2 Regulatory Overview
7.2.2.3 Clinical Overview
7.2.3 Tecentriq (Atezolizumab)
7.2.3.1 Overview
7.2.3.2 Commercial Overview
7.2.3.3 Clinical Overview
7.2.4 Imfinzi (Durvalumab)
7.2.4.1 Overview
7.2.4.2 Commercial Overview
7.2.4.3 Clinical Overview
7.3 Promising Products in Development
7.3.1 HLX10 (Serplulimab/Hansizhuang)
7.3.1.1 Overview
7.3.1.2 Commercial Overview
7.3.1.2.1 Regulatory Overview
7.3.1.3 Clinical Overview
7.3.2 Socazolimab (ZKAB001)
7.3.2.1 Overview
7.3.2.2 Commercial Overview
7.3.2.2.1 Regulatory Overview
7.3.2.3 Clinical Overview
7.3.3 SHR-1316 (Adebrelimab)
7.3.3.1 Overview
7.3.3.2 Commercial Overview
7.3.3.2.1 Regulatory Overview
7.3.4 Tislelizumab
7.3.4.1 Overview
7.3.4.2 Commercial Overview
7.3.4.3 Clinical Overview

8 Competitive Benchmarking and Company Profiles
8.1 F. Hoffmann-La Roche Ltd
8.1.1 Company Overview
8.1.2 Role of F. Hoffmann-La Roche Ltd in Global Extensive Stage Small Cell Lung Cancer Market
8.1.3 Product Portfolio
8.1.4 Key Competitors of the Company
8.1.5 Financials
8.1.6 Key Insights about the Financial Health of the Company
8.1.7 Business Strategies
8.1.8 Corporate Strategies
8.1.9 Analyst’s Perspective
8.2 AstraZeneca PLC
8.2.1 Company Overview
8.2.2 Role of AstraZeneca PLC in Global Extensive Stage Small Cell Lung Cancer Market
8.2.3 Product Portfolio
8.2.4 Key Competitors of the Company
8.2.5 Financials
8.2.6 Key Insights about the Financial Health of the Company
8.2.7 Business Strategies
8.2.8 Analyst’s Perspective
8.3 Jazz Pharmaceuticals Plc
8.3.1 Company Overview
8.3.2 Role of Jazz Pharmaceuticals Plc in Global Extensive Stage Small Cell Lung Cancer Market
8.3.3 Product Portfolio
8.3.4 Key Competitors of the Company
8.3.5 Financials
8.3.6 Key Insights about the Financial Health of the Company
8.3.7 Business Strategies
8.3.8 Corporate Strategies
8.3.9 Analyst’s Perspective
8.4 G1 Therapeutics Inc.
8.4.1 Company Overview
8.4.2 Role of G1 Therapeutics Inc. in Global Extensive Stage Small Cell Lung Cancer Market
8.4.3 Product Portfolio
8.4.4 Key Competitors of the Company
8.4.5 Financials
8.4.6 Key Insights about the Financial Health of the Company
8.4.7 Business Strategies
8.4.8 Corporate Strategies
8.4.9 Analyst’s Perspective
8.5 Shanghai Henlius Biotech, Inc.
8.5.1 Company Overview
8.5.2 Role of Shanghai Henlius Biotech, Inc. in Global Extensive Stage Small Cell Lung Cancer Market
8.5.3 Product Portfolio
8.5.4 Key Competitors of the Company
8.5.5 Financials
8.5.6 Key Insights about the Financial Health of the Company
8.5.7 Business Strategies
8.5.8 Analyst’s Perspective
8.6 Lee’s Pharmaceutical Limited
8.6.1 Company Overview
8.6.2 Role of Lee’s Pharmaceutical Limited in Global Extensive Stage Small Cell Lung Cancer Market
8.6.3 Product Portfolio
8.6.4 Key Competitors of the Company
8.6.5 Financials
8.6.6 Key Insights about the Financial Health of the Company
8.6.7 Business Strategies
8.6.8 Analyst’s Perspective
8.7 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
8.7.1 Company Overview
8.7.2 Role of Jiangsu Hengrui Pharmaceuticals Co., Ltd. in Global Extensive Stage Small Cell Lung Cancer Market
8.7.3 Product Portfolio
8.7.4 Key Competitors of the Company
8.7.5 Financials
8.7.6 Key Insights about the Financial Health of the Company
8.7.7 Business Strategies
8.7.8 Corporate Strategies
8.7.9 Analyst’s Perspective
8.8 Beigene Ltd.
8.8.1 Company Overview
8.8.2 Role of Beigene Ltd. in Global Extensive Stage Small Cell Lung Cancer Market
8.8.3 Product Portfolio
8.8.4 Key Competitors of the Company
8.8.5 Financials
8.8.6 Key Insights about the Financial Health of the Company
8.8.7 Corporate Strategies
8.8.8 Analyst’s Perspective
9 BIS Research Recommendations
9.1 Current Market Scenario
9.2 Future Scenario
9.3 Key Success Factors and Challenges
9.3.1 Success Factors
9.3.2 Key Challenges
List of Figures
Figure 1: Extensive Stage Small Cell Lung Cancer Incidence Growth Rate, 2022-2032
Figure 2: Extensive Stage Small Cell Lung Cancer Prevalence Growth Rate, 2022-2032
Figure 3: Leading Drug Class in Clinical Trials for Extensive Stage Small Cell Lung Cancer Market
Figure 4: Global Extensive Stage Small Cell Lung Cancer Market Segmentation
Figure 5: Global Extensive Stage Small Cell Lung Cancer Market Methodology
Figure 6: Primary Research Methodology
Figure 7: Companies Actively Pursuing Clinical Development for Extensive Stage Small Cell Lung Cancer
Figure 8: Number of Strategic Activities
Figure 9: Regional Distribution of Companies
Figure 10: Lung Cancer Types
Figure 11: Disease Pathophysiology
Figure 12: Extensive Stage Small Cell Lung Cancer Treatment Types
Figure 13: Extensive Stage Small Cell Lung Cancer Treatment Algorithm
Figure 14: Extensive Stage Small Cell Lung Cancer Patient Journey
Figure 15: U.S. Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 16: U.S. Prevalence of Extensive Stage Small Cell Lung Cancer, 2022-2032
Figure 17: U.K. Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 18: U.K. Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 19: Germany Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 20: Germany Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 21: France Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 22: France Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 23: Italy Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 24: Italy Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 25: Spain Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 26: Spain Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 27: Japan Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 28: Japan Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 29: Number of Extensive Stage Small Cell Lung Cancer Clinical Trials
Figure 30: Clinical Trials by Drug Class
Figure 31: Clinical Trials by Monotherapy/Combination Type
Figure 32: Zepzelca (Lurbinectedine) Annual Sales ($Million), 2020 and 2021
Figure 33: Tecentriq Annual Sales ($Million), 2019-2021
Figure 34: Imfinzi Annual Sales ($Million), 2020 and 2021
Figure 35: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 36: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
Figure 37: F. Hoffmann-La Roche Ltd: Net Revenue (by Segment), $Million, 2019-2021
Figure 38: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
Figure 39: AstraZeneca PLC: Product Portfolio
Figure 40: AstraZeneca PLC: Overall Financials, $Million, 2019-2021
Figure 41: AstraZeneca PLC: Net Revenue (by Region), $Million, 2019-2021
Figure 42: AstraZeneca PLC: R&D Expenditure, $Million, 2019-2021
Figure 43: Jazz Pharmaceuticals Plc: Product Portfolio
Figure 44: Jazz Pharmaceuticals Plc: Overall Financials, $Million, 2019-2021
Figure 45: Jazz Pharmaceuticals Plc: R&D Expenditure, $Million, 2019-2021
Figure 46: G1 Therapeutics Inc.: Product Portfolio
Figure 47: G1 Therapeutics Inc.: Overall Financials, $Million, 2019-2021
Figure 48: G1 Therapeutics Inc.: R&D Expenditure, $Million, 2019-2021
Figure 49: Shanghai Henlius Biotech, Inc.: Product Portfolio
Figure 50: Shanghai Henlius Biotech, Inc.: Overall Financials, $Million, 2019-2021
Figure 51: Shanghai Henlius Biotech, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 52: Lee’s Pharmaceutical Limited: Product Portfolio
Figure 53: Lee’s Pharmaceutical Limited: Overall Financials, $Million, 2019-2021
Figure 54: Lee’s Pharmaceutical Limited: R&D Expenditure, $Million, 2019-2021
Figure 55: Jiangsu Hengrui Pharmaceuticals Co., Ltd.: Product Portfolio
Figure 56: Jiangsu Hengrui Pharmaceuticals Co., Ltd.: Overall Financials, $Million, 2019-2021
Figure 57: Jiangsu Hengrui Pharmaceuticals Co., Ltd.: R&D Expenditure, $Million, 2019-2021
Figure 58: Beigene Ltd.: Product Portfolio
Figure 59: Beigene Ltd.: Overall Financials, $Million, 2019-2021
Figure 60: Beigene Ltd.: R&D Expenditure, $Million, 2019-2021
List of Tables
Table 1: Extensive Stage Small Cell Lung Cancer Prevalence in Seven Major Markets, 2022-2032
Table 2: Global Extensive Stage Small Cell Lung Cancer Market Snapshot
Table 3: HLX-10 (Serplulimab/Hansizhuang) from Shanghai Henlius Biotech in Comparison with Approved Products of the Global Extensive Stage Small Cell Lung Cancer Market
Table 4: Jiangsu Hengrui Pharmaceuticals Co., Ltd. Extensive Stage Small Cell Lung Cancer Pipeline
Table 5: Competitive Landscape Snapshot
Table 6: Potential Immune Checkpoint Inhibitors Under Clinical Development
Table 7: Different Drug Classes Under Development for Treatment of Extensive Stage Small Cell Lung Cancer
Table 8: Veterans’ Administration (VA) Lung Group Classification Scheme
Table 9: Advantages and Disadvantages of Chemotherapy Treatment
Table 10: Advantages and Disadvantages of Radiation Therapy
Table 11: FDA Approved Immunotherapies for Treatment of Extensive Stage Small Cell Lung Cancer
Table 12: Advantages and Disadvantages of Immunotherapy
Table 13: NCCN and NICE Treatment Guidelines
Table 14: Clinical Trials by Route of Administration (RoA)
Table 15: Combination Therapies Under Clinical Trial
Table 16: Leading Monotherapies Under Clinical Trial
Table 17: Marketed Products Indicated for the Treatment of Extensive Stage Small Cell Lung Cancer
Table 18: Zepzelca (Lurbinectedine) Key Regulatory Events
Table 19: Promising Products in Development
Table 20: Clinical Trial Details of HLX-10 (Serplulimab/Hansizhuang)
Table 21: Clinical Trial Details of HLX-10
Table 22: Clinical Trial Details of Socazolimab (ZKAB001)
Table 23: Clinical Trial Details of SHR-1316 (Adebrelimab)
Table 24: Phase Three Clinical Trial Result of SHR-1316 (Adebrelimab)
Table 25: F. Hoffmann-La Roche Ltd: Key Competitors
Table 26: AstraZeneca PLC: Key Competitors
Table 27: Shanghai Henlius Biotech, Inc.: Key Competitors
Table 28: Lee’s Pharmaceutical Limited: Key Competitors
Table 29: Jiangsu Hengrui Pharmaceuticals Co., Ltd.’s Extensive State SCLC Products’ Clinical Trials
Table 30: Jiangsu Hengrui Pharmaceuticals Co., Ltd.: Key Competitors
Table 31: Beigene Ltd.: Key Competitors